Breaking News Instant updates and real-time market news.

ALIOF

Actelion

$184.01

30.46 (19.84%)

, JNJ

Johnson & Johnson

$113.48

-0.65 (-0.57%)

13:29
11/28/16
11/28
13:29
11/28/16
13:29

Actelion mulls complex transaction to combine with part of J&J, FT says

Actelion (ALIOF) is weighing a complicated deal to merge with part of Johnson & Johnson (JNJ), a move that will leave the Swiss company independent from the U.S. company, the Financial Times reports, citing people close to the discussions. The structured deal would establish a new, larger biotech company uniting Actelion with relevant parts of Johnson & Johnson's pharma operations, the report says, citing people involved in the talks. The U.S. company would become a major stakeholder in the new entity and could be asked to add come cash to complete the transaction, the report says. Actelion is not actively mulling selling itself outright, the report says. Reference Link

ALIOF

Actelion

$184.01

30.46 (19.84%)

JNJ

Johnson & Johnson

$113.48

-0.65 (-0.57%)

  • 29

    Nov

ALIOF Actelion
$184.01

30.46 (19.84%)

11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
JNJ Johnson & Johnson
$113.48

-0.65 (-0.57%)

10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

JKHY

Jack Henry

$125.32

0.17 (0.14%)

17:12
01/22/18
01/22
17:12
01/22/18
17:12
Initiation
Jack Henry initiated  »

Jack Henry initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIZ

Assurant

$94.03

-0.05 (-0.05%)

17:10
01/22/18
01/22
17:10
01/22/18
17:10
Syndicate
Breaking Syndicate news story on Assurant »

Assurant files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

FSLR

First Solar

$68.96

-1.07 (-1.53%)

17:08
01/22/18
01/22
17:08
01/22/18
17:08
Technical Analysis
Technical Take: First Solar spikes after tariff decision »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$52.25

-0.25 (-0.48%)

17:05
01/22/18
01/22
17:05
01/22/18
17:05
Earnings
Brown & Brown reports Q4 EPS 47c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EAT

Brinker

$38.39

0.08 (0.21%)

, GS

Goldman Sachs

$261.52

5.4 (2.11%)

17:03
01/22/18
01/22
17:03
01/22/18
17:03
Hot Stocks
Brinker adds James Katzman To Board of Directors »

Brinker (EAT) announces…

EAT

Brinker

$38.39

0.08 (0.21%)

GS

Goldman Sachs

$261.52

5.4 (2.11%)

HSY

Hershey

$109.96

0.59 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

  • 01

    Feb

CCXI

ChemoCentryx

$8.31

-0.04 (-0.48%)

17:01
01/22/18
01/22
17:01
01/22/18
17:01
Hot Stocks
ChemoCentryx reports 'positive' survival results from CCX872 trial »

ChemoCentryx announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

NWHM

New Home Company

$12.89

0.01 (0.08%)

16:58
01/22/18
01/22
16:58
01/22/18
16:58
Syndicate
Breaking Syndicate news story on New Home Company »

New Home Company files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TROW

T. Rowe Price

$117.40

0.05 (0.04%)

16:57
01/22/18
01/22
16:57
01/22/18
16:57
Hot Stocks
T. Rowe Price sees FY18 effective tax rate 24%-27% »

On December 22, 2017, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$75.83

0.23 (0.30%)

16:45
01/22/18
01/22
16:45
01/22/18
16:45
Hot Stocks
Natixis, NYSE enter licensing agreement »

Natixis Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$21.21

1.72 (8.83%)

16:43
01/22/18
01/22
16:43
01/22/18
16:43
Syndicate
Breaking Syndicate news story on Catalyst Biosciences »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRET

Investors Real Estate

$5.74

0.03 (0.53%)

16:40
01/22/18
01/22
16:40
01/22/18
16:40
Hot Stocks
Investors Real Estate completes sale of two additional medical office buildings »

IRET completed the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIC

Flushing Financial

$28.93

-0.1 (-0.34%)

16:39
01/22/18
01/22
16:39
01/22/18
16:39
Hot Stocks
Flushing Financial announces dividend plans for 2018 »

Flushing Financia, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

JMBA

Jamba

$9.14

-0.01 (-0.11%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Syndicate
Jamba 2.1M share Block Trade; price range $8.25-$8.40 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULT

Fulton Financial

$18.65

0.1 (0.54%)

16:37
01/22/18
01/22
16:37
01/22/18
16:37
Earnings
Fulton Financial reports Q4 EPS 19c, consensus 28c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36
Hot Stocks
Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study »

Amgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN

Amgen

$192.33

3.05 (1.61%)

16:34
01/22/18
01/22
16:34
01/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen: Aimovig met all…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

FL

Foot Locker

$50.37

0.16 (0.32%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
Foot Locker makes strategic investment in Carbon38 »

Foot Locker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPE

EP Energy

$2.48

0.17 (7.36%)

16:32
01/22/18
01/22
16:32
01/22/18
16:32
Hot Stocks
EP Energy sees FY18 $600M-$650M of oil and gas expenditures, »

Sees FY18 81…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$98.06

-0.98 (-0.99%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Darden names Dave George as COO »

Darden Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

, WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

16:31
01/22/18
01/22
16:31
01/22/18
16:31
Hot Stocks
Rite Aid provides update on sale of assets to Walgreens Boots Alliance »

Rite Aid Corporation…

RAD

Rite Aid

$2.29

-0.02 (-0.87%)

WBA

Walgreens Boots Alliance

$77.40

0.93 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$54.16

0.43 (0.80%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Earnings
Zions Bancorp reports Q4 adjusted EPS 80c, consensus 73c »

Harris H. Simmons,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
EP Energy reports preliminary FY17 production results of 82,300MBoe/d »

Preliminary FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

RMD

ResMed

$87.51

-1.17 (-1.32%)

16:30
01/22/18
01/22
16:30
01/22/18
16:30
Hot Stocks
Breaking Hot Stocks news story on ResMed »

ResMed up 8.5% to $95.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.